

New Submissions November 2020

Methylphenidate and Dexamphetamine	To become AMBER 2	Narcolepsy	To be amended on the formulary once the prescribing information guides are ready (before the end of December)
Fluticasone furoate/ vilanterol Ellipta Inhaler (Relvar®)	AMBER 2	Asthma	For patients with severe asthma being treated at Step 4 of the BTS guidance
Naldemedine ▼	AMBER 2	Opioid induced constipation	As per NICE TA 651 May offer a cost effective alternative to naloxegol

News from the APC - updated/new documents on the APC website:

- [Lamotrigine in Bipolar Disorder information sheet](#) (Update)
- [End of life guidelines](#) (Update)
- [Dermatology SCP](#) and [information sheets](#) (Update)
- [Inflammatory bowel disease SCP](#) and [information sheets](#) (Update)
- [Neuroinflammatory conditions SCP](#) and [information sheet](#) (Update)
- [High dose opioid patient information leaflet](#) (New)
- [Hyperlipidaemia guidelines](#) (Update)
- [Limited clinical value medicines list](#) (Update)



Co-proxamol prescribing:

Licence withdrawn in 2007 due to safety concerns - serious effects on electrical activity of the heart even at normal therapeutic doses. Risk of addiction and increased risk of death in overdose.

A lot of work has gone into switching patients to safer alternatives, but there are still EIGHT practices in Nottinghamshire that have one or more patients still on it. Please discuss with your CCG medicines optimisation pharmacist if you need support in reviewing these patients.

Current work in progress:

- Asthma in adults guideline
- Sleep and melatonin guidance
- Adult ADHD Shared Care
- End stage heart failure pocket book
- Premature infant feeding guidelines
- Renal calculator position statement
- Bowen's Disease Pathway
- Omeprazole liquid review process
- COPD Guideline
- Rosacea Guideline
- Fludrocortisone information sheet

Horizon Scanning, Formulary amendments and traffic light changes

Formulary amendments:

- **Lecicarbon C** - Temporary reclassification to **Green** for paediatric patients currently using bisacodyl suppositories which are currently unavailable.
- **Ceftriaxone** - Added to local meningitis guidance as an option for treatment whilst cefotaxime unavailable.
- **Clonidine** - classified as **Amber 2** for patients with Tourette's syndrome.
- **Adrenaline** 1 in 1000 topical solution to reduce surface bleeding in palliative care - Classified as **Amber 2** on palliative care advice.
- **Lacosamide, brivaracetam, perampanel and eslicarbazepine** - for adults, the restriction that patients need to be stabilised prior to transfer to primary care has been removed. With the caveat that clear guidance on dose titration and maximum doses should be provided by the Neurologist.
- **Combined Hormonal Contraceptives** - clarity about tailored regimens added.
- **Methylphenidate** MR capsules (Ritalin XL) - brand added as an option for prescribers.
- **Acidex oral suspension** - Added as **Green** as a second line option after Peptac.
- **Testosterone gel** - Low libido in post menopausal women, clarified as **Grey**.
- **Testosterone gel** - replacement therapy for adult male hypogonadism, Testogel pump added as a cost effective choice - should be prescribed by brand.
- **Lofexidine** - discontinued and amended to **Grey**.
- **Metformin** - **Amber 2** for antipsychotic associated weight gain.
- **Risperidone orodispersible** tablets - **Grey**, liquid more cost effective if needed.
- **Viridal Duo** - temporarily classified as **Amber 2** where Caverject is unavailable.

Horizon scanning:

- Grey, no formal assessment:
Bempedonic acid, Syncrocin (Melatoin), Xenleta (Iefamulin), Myopridin (pridinol), vardenafil oro-dispersible tabs,
- Grey, awaiting assessment:
Canagliflozin now licensed for diabetic kidney disease and dapagliflozin now licensed for heart failure.

Upcoming NICE publications

Title	Type	Publication date
Liraglutide for managing overweight and obesity	TA	December 2020
Diabetes in pregnancy: management from preconception to the postnatal period	Guidance	December 2020
Diabetes (type 1 and type 2) in children and young people: diagnosis and management	Guidance	December 2020
Chronic pain: assessment and management	Guidance	Jan 2021
AF management	Guidance	Feb 2021
Dapagliflozin for treating heart failure with reduced ejection fraction	TA	Feb 2021
Secondary infection of common skin conditions including eczema: antimicrobial prescribing	Guidance	March 2021
Esketamine for treatment-resistant depression	TA	TBC



[Prescribing issues logs and the SFH prescribing queries portal](#) have been re-launched! Please complete the logs to enable us to identify trends and issues that can be raised with Secondary Care. They can be accessed via the button on the [formulary homepage](#).